The Preventive Effect of Specific Collagen Peptides against Dexamethasone-Induced Muscle Atrophy in Mice
Molecules · 2023
DOI: 10.3390/molecules28041950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Jieun Oh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea. Hauptthemen laut MEDLINE: Muscular Atrophy, Myostatin, Collagen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, National Research Foundation of Korea (NRF), the Ministry of Science and ICT, COSMAX NBT.
Abstract (Originalsprache)
Muscle atrophy, also known as muscle wasting, is the thinning of muscle mass due to muscle disuse, aging, or diseases such as cancer or neurological problems. Muscle atrophy is closely related to the quality of life and has high morbidity and mortality. However, therapeutic options for muscle atrophy are limited, so studies to develop therapeutic agents for muscle loss are always required. For this study, we investigated how orally administered specific collagen peptides (CP) affect muscle atrophy and elucidated its molecular mechanism using an in vivo model. We treated mice with dexamethasone (DEX) to induce a muscular atrophy phenotype and then administered CP (0.25 and 0.5 g/kg) for four weeks. In a microcomputed tomography analysis, CP (0.5 g/kg) intake significantly increased the volume of calf muscles in mice with DEX-induced muscle atrophy. In addition, the administration of CP (0.25 and 0.5 g/kg) restored the weight of the gluteus maximus and the fiber cross-sectional area (CSA) of the pectoralis major and calf muscles, which were reduced by DEX. CP significantly inhibited the mRNA expression of myostatin and the phosphorylation of Smad2, but it did not affect TGF-β, BDNF, or FNDC5 gene expression. In addition, AKT/mTOR, a central pathway for muscle protein synthesis and related to myostatin signaling, was enhanced in the groups that were administered CP. Finally, CP decreased serum albumin levels and increased TNF-α gene expression. Collectively, our in vivo results demonstrate that CP can alleviate muscle wasting through a multitude of mechanisms. Therefore, we propose CP as a supplement or treatment to prevent muscle atrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea.
- Department of Biocosmetics, Sungkyunkwan University, Suwon 16419, Republic of Korea.
- COSMAX NS, INC., Seongnam 13487, Republic of Korea.
- COSMAX NBT, INC., Seongnam 13487, Republic of Korea.
ORCID-Profile: Sang Hee Park, Laily Rahmawati, Won Young Jang, Jae Youl Cho
Förderung
- National Research Foundation of Korea
- National Research Foundation of Korea (NRF), the Ministry of Science and ICT
- COSMAX NBT
Zitieren
APA
Oh, J., Park, S. H., Kim, D. S., Choi, W., Jang, J., Rahmawati, L., Jang, W. Y., Lim, H. K., Hwang, J. Y., Gu, G. R., Geum, J. H., Choi, S. Y., Kim, J. H., & Cho, J. Y. (2023). The Preventive Effect of Specific Collagen Peptides against Dexamethasone-Induced Muscle Atrophy in Mice. Molecules. https://doi.org/10.3390/molecules28041950
Vancouver
Oh J, Park SH, Kim DS, Choi W, Jang J, Rahmawati L, et al. The Preventive Effect of Specific Collagen Peptides against Dexamethasone-Induced Muscle Atrophy in Mice. Molecules. 2023. doi:10.3390/molecules28041950
BibTeX
@article{Oh2023,
author = {Oh, Jieun and Park, Sang Hee and Kim, Dong Seon and Choi, Wooram and Jang, Jiwon and Rahmawati, Laily and Jang, Won Young and Lim, Hyun Kyung and Hwang, Ji Yeon and Gu, Ga Rin and Geum, Jeong-Ho and Choi, Su-Young and Kim, Ji Hye and Cho, Jae Youl},
title = {The Preventive Effect of Specific Collagen Peptides against Dexamethasone-Induced Muscle Atrophy in Mice},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28041950}
}
EUVIMED